Table 1.
Patient characteristics.
| D-MS HR (n = 45) | D-MS LR (n = 51) | p-value | |
|---|---|---|---|
| MS, median (range) | 1.62 (0.78–3.45) | 1.95 (1.7–2.28) | 0.382 |
| Age at diagnosis, median (range) [years] | 58 (31–82) | 64 (38–83) | 0.141 |
| Age at sample, median (range) [years] | 66 (38–83) | 68 (42–88) | 0.220 |
| Age ≥ 65 years, n (%) | 26 (58) | 30 (59) | 0.473 |
| Age ≥ 75 years, n (%) | 6 (13) | 13 (25) | 0.123 |
| Sex, male/female, n | 29/16 | 28/23 | 0.229 |
| Median time from diagnosis to sample, median (range) [months] | 72 (0–194) | 56 (0–247) | 0.580 |
| WBC at sample, median (range) [/nl] | 70 (19–262) | 55 (17–234) | 0.069 |
| PB lymphocytes, median (range) [%] | 93 (74–100) | 91 (67–100) | 0.121 |
| Previous treatment, n (%) | 13 (29) | 11 (22) | 0.203 |
| Prior treatments, median (range) | 0 (0–9) | 0 (0–4) | 0.299 |
| Treatment after sample, n (%) | 22 (49) | 20 (39) | 0.227 |
| Novel treatment after sample, n (%) | 7 (16) | 8 (16) | 0.610 |
| Ibrutinib, n (%) | 6 (13) | 4 (8) | 0.293 |
| Idelalisib, n (%) | 3 (6) | 4 (8) | 0.570 |
| ABT-199, n (%) | 0 | 1 (2) | 0.531 |
| Binet at diagnosis, A/B/C/unknown [n] | 26/11/1/7 | 38/5/2/6 | 0.193 |
| LDT at sample, median (mean; range) [months] | 12 (20; 1–62) | 26 (34; 3–80) | 0.166 |
| Cytogenetic abnormalities | |||
| del11q22–23, n (%) | 8/45 (18) | 6/47 (13) | 0.570 |
| Trisomy 12, n (%) | 6/44 (14) | 11/47 (23) | 0.287 |
| del13q14, n (%) | 31/44 (70) | 28/48 (58) | 0.321 |
| del17p13, n (%) | 7/44 (16) | 4/47 (9) | 0.259 |
| IGHV unmutated | 18/35 (51) | 16/38 (42) | 0.681 |
| NOTCH1 mutation, n (%) | 4/41 (10) | 3/44 (7) | 0.460 |
| SF3B1 mutation, n (%) | 6/40 (15) | 5/44 (11) | 0.755 |
| TP53 mutation, n (%) | 9/41 (22) | 5/45 (11) | 0.356 |
| Del17p13 and/or TP53 mutation | 10/40 (25) | 8/42 (19) | 0.795 |